These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 18573339)

  • 1. Immunogenic anti-cancer chemotherapy as an emerging concept.
    Haynes NM; van der Most RG; Lake RA; Smyth MJ
    Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunological aspects of anticancer chemotherapy].
    Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
    Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.
    van der Most RG; Currie AJ; Robinson BW; Lake RA
    Cell Death Differ; 2008 Jan; 15(1):13-20. PubMed ID: 18007666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells and their role in cancer immunotherapy.
    Jalili A
    Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 'kiss of death' by dendritic cells to cancer cells.
    Chan CW; Housseau F
    Cell Death Differ; 2008 Jan; 15(1):58-69. PubMed ID: 17948029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic cancer cell death: a key-lock paradigm.
    Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
    Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer.
    Wesa AK; Storkus WJ
    Cell Death Differ; 2008 Jan; 15(1):51-7. PubMed ID: 17948028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene transfer approaches in cancer immunotherapy.
    Larin SS; Georgiev GP; Kiselev SL
    Gene Ther; 2004 Oct; 11 Suppl 1():S18-25. PubMed ID: 15454953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor stress, cell death and the ensuing immune response.
    Ullrich E; Bonmort M; Mignot G; Kroemer G; Zitvogel L
    Cell Death Differ; 2008 Jan; 15(1):21-8. PubMed ID: 17992190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity.
    Calderwood SK; Theriault JR; Gong J
    Eur J Immunol; 2005 Sep; 35(9):2518-27. PubMed ID: 16144035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve immunotherapy drugs that could cure cancers.
    Cheever MA
    Immunol Rev; 2008 Apr; 222():357-68. PubMed ID: 18364014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new era for innate immunity.
    Montero Vega MT
    Allergol Immunopathol (Madr); 2008; 36(3):164-75. PubMed ID: 18680705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate and adaptive immune pathways to tolerance.
    Thornton CA; Morgan G
    Nestle Nutr Workshop Ser Pediatr Program; 2009; 64():45-57; discussion 57-61, 251-7. PubMed ID: 19710514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.
    Radfar S; Wang Y; Khong HT
    J Immunol; 2009 Nov; 183(10):6800-7. PubMed ID: 19846868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma.
    McCoy MJ; Nowak AK; Lake RA
    Tissue Antigens; 2009 Jul; 74(1):1-10. PubMed ID: 19422663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characteristics of immunogenic cancer cell death.
    Tesniere A; Panaretakis T; Kepp O; Apetoh L; Ghiringhelli F; Zitvogel L; Kroemer G
    Cell Death Differ; 2008 Jan; 15(1):3-12. PubMed ID: 18007663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific and non-specific responses in host resistance to tumors.
    Baldwin RW
    Tokai J Exp Clin Med; 1983 Dec; 8(5-6):419-28. PubMed ID: 6398929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.